1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Hepatic (Liver) Tumor - Pipeline Review, H2 2014

Hepatic (Liver) Tumor - Pipeline Review, H2 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 31 pages

Hepatic (Liver) Tumor - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Hepatic (Liver) Tumor - Pipeline Review, H2 2014’, provides an overview of the Hepatic (Liver) Tumor’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatic (Liver) Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic (Liver) Tumor and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hepatic (Liver) Tumor
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hepatic (Liver) Tumor and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hepatic (Liver) Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hepatic (Liver) Tumor pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hepatic (Liver) Tumor
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hepatic (Liver) Tumor pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Hepatic (Liver) Tumor - Pipeline Review, H2 2014
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Hepatic (Liver) Tumor Overview 6
Therapeutics Development 7
Pipeline Products for Hepatic (Liver) Tumor - Overview 7
Pipeline Products for Hepatic (Liver) Tumor - Comparative Analysis 8
Hepatic (Liver) Tumor - Therapeutics under Development by Companies 9
Hepatic (Liver) Tumor - Therapeutics under Investigation by Universities/Institutes 10
Hepatic (Liver) Tumor - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Hepatic (Liver) Tumor - Products under Development by Companies 13
Hepatic (Liver) Tumor - Products under Investigation by Universities/Institutes 14
Hepatic (Liver) Tumor - Companies Involved in Therapeutics Development 15
APAvadis Biotechnologies Srl 15
Samumed 16
Hepatic (Liver) Tumor - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
Gene Therapy for Liver Metastases and Primary Liver Tumors - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
MPT-0E028 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Peptides for Cancer and Endometriosis - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Peptides to Inhibit Aminopeptidase A for Cancer and Endometriosis - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
SM-04755 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Hepatic (Liver) Tumor - Dormant Projects 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31

List of Tables

Number of Products under Development for Hepatic (Liver) Tumor, H2 2014 7
Number of Products under Development for Hepatic (Liver) Tumor - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Hepatic (Liver) Tumor - Pipeline by APAvadis Biotechnologies Srl, H2 2014 15
Hepatic (Liver) Tumor - Pipeline by Samumed, H2 2014 16
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Stage and Target, H2 2014 18
Number of Products by Stage and Mechanism of Action, H2 2014 19
Number of Products by Stage and Route of Administration, H2 2014 21
Number of Products by Stage and Molecule Type, H2 2014 23
Hepatic (Liver) Tumor - Dormant Projects, H2 2014 29

List of Figures

Number of Products under Development for Hepatic (Liver) Tumor, H2 2014 7
Number of Products under Development for Hepatic (Liver) Tumor - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Products, H2 2014 12
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Top 10 Routes of Administration, H2 2014 20
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 20
Number of Products by Top 10 Molecule Types, H2 2014 22
Number of Products by Stage and Top 10 Molecule Types, H2 2014 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by GlobalData

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

Immunotherapy Drugs Market by Type of Drugs, Therapy Area, End-User, Region - Global Forecast to 2021

Immunotherapy Drugs Market by Type of Drugs, Therapy Area, End-User, Region - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The global immunotherapy drugs market is projected to reach USD 201.52 billion by 2021 from USD 108.41 billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021. In this report, ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.